Copolymers of Poly(Butylene Trans‐1,4‐Cyclohexanedicarboxylate)/Pripol as New Biomaterial Platform for Small Diameter Vascular Graft

Autologous grafts remain the clinical gold standard for vascular reconstruction; however, their use is limited by donor site morbidity, poor availability, and long-term failure. Synthetic alternatives, while effective in large-caliber vessels, fail in small-diameter applications (<6 mm) due to thrombosis, intimal hyperplasia, and biomechanical mismatch. In this context, tissue-engineered vascular grafts (TEVGs) emerge as a solution, requiring biomaterials that closely replicate the structural, mechanical, and hemocompatible properties of native vessels. Aliphatic polyesters such as polylactic acid, polyglycolic acid, and poly(ε-caprolactone) are extensively studied but show poor endothelialization and mechanical deficiency. In contrast, poly(butylene trans-1,4-cyclohexanedicarboxylate) (PBCE) attracts interest for its biocompatibility, thermal stability, and processability. Its copolymerization with Pripol 1009, a commercial fatty diacid, enables modulation of mechanical properties and degradation rate, two of the key parameters for vascular engineering. In this work, electrospun scaffolds based on these copolymers are fabricated in flat and tubular formats and characterized in terms of morphology, mechanical behavior, hemocompatibility, and endothelialization potential. Certain formulations display mechanical properties comparable to native vessels, support endothelialization and smooth muscle cell adhesion, and do not trigger coagulation pathways in in vitro assays. These results identify PBCE/Pripol copolymers as promising candidates for next-generation TEVGs, bridging the gap between synthetic reliability and biological performance in small-diameter vascular applications.